
Current Price | $0.09 | Mkt Cap | $3.2M |
---|---|---|---|
Open | $0.09 | P/E Ratio | -0.18 |
Prev. Close | $0.09 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.09 - $0.09 | Volume | 3,062,919 |
52-Wk Range | $0.08 - $1.05 | Avg. Daily Vol. | 1,846,846 |
Current Price | $0.09 | Mkt Cap | $3.2M |
---|---|---|---|
Open | $0.09 | P/E Ratio | -0.18 |
Prev. Close | $0.09 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.09 - $0.09 | Volume | 3,062,919 |
52-Wk Range | $0.08 - $1.05 | Avg. Daily Vol. | 1,846,846 |
The best Bull and Bear pitches based on recency and number of recommendations.
As of 10/19/11, Neoprobe's New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the FDA.
Extremely overvalued trash stock.
Read the most recent pitches from players about NAVB.
Recs
$NAVB basing near the $ once again. New management and great potential with their new platform under Goldberg. Gonzalez as the new CEO pushing the marketing potential for Lymphoseek. $2+ short term potential imo.
Recs
NAVB will outperform the market over the next 5 years, but due to its burn rate on R&D and G&A, it will go through a number of rounds of financing that will dilute out shareholders. This stock will excel, but there are stocks that are closer to monetizing shareholdeer value
Recs
No competition.
Extremely undervalued.
Find the members with the highest scoring picks in NAVB.
Europecv (27.03) Score: +358.99
The Score Leader is the player with the highest score across all their picks in NAVB.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
capostatus | 28.50 | 10/12/2010 |
![]() |
5Y | $1.65 | -94.42% | +259.96% | +354.39 | 0 Comment | |
stockjock11 | 45.90 | 3/26/2010 |
![]() |
NS | $1.72 | -94.65% | +256.24% | +350.90 | 1 Comment | |
Europecv | 27.03 | 11/23/2010 |
![]() |
5Y | $1.82 | -94.95% | +252.93% | +347.88 | 0 Comment | |
Caboverde | 27.05 | 10/22/2010 |
![]() |
5Y | $1.62 | -94.32% | +253.08% | +347.40 | 0 Comment | |
TheChozen1 | 27.20 | 10/22/2010 |
![]() |
5Y | $1.60 | -94.25% | +252.93% | +347.18 | 0 Comment | |
SuperNova007 | 99.12 | 4/9/2010 |
![]() |
5Y | $1.79 | -94.86% | +250.65% | +345.51 | 0 Comment | |
BuffettJunior1 | 98.79 | 10/17/2011 |
![]() |
5Y | $3.02 | -96.95% | +244.68% | +341.63 | 1 Comment | |
walt393 | 99.87 | 12/15/2011 |
![]() |
5Y | $2.46 | -96.26% | +239.22% | +335.48 | 0 Comment | |
williamstep | 98.00 | 6/3/2011 |
![]() |
5Y | $4.70 | -98.04% | +220.66% | +318.70 | 0 Comment | |
jrokket731 | 56.82 | 2/25/2011 |
![]() |
5Y | $4.60 | -98.00% | +215.93% | +313.93 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.